Ed Miseta

Ed Miseta

Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.


  • How BMS Uses AI To Improve Study Design And Reduce Costs

    In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.

  • Clinical Sites Are Optimistic, Despite Growing Challenges

    The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.

  • DTRA Looks At The Future Of Decentralized Trials

    In November 2022, the Decentralized Trials & Research Alliance (DTRA) held its annual meeting in Boston. The meeting was a chance for members of the Alliance to come together to discuss the progress that has been made and what the future holds for the emerging technology.

  • How One Pharma Company Is Embracing Digital Technologies

    The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

  • The Future Of TransCelerate: Clinical Trial Modernization

    In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

  • Overcome Recruitment Challenges Of Black And Rural Patients

    Patient recruitment for clinical trials is difficult and can cause many studies to be delayed or cancelled. Two groups that are particularly difficult to recruit are patients of color and those living in remote and rural areas of the country. In those two instances, overcoming recruitment barriers can prove to be particularly difficult.

  • How To Educate Regulators On What Matters To Patients

    With the greater emphasis on patient-centricity, patients are valued as an active participant in their own care. There is an increased emphasis on evaluating treatment benefit using patient-centric concepts and input from the patient community. Regulators now urge sponsors and researchers to systematically engage patients and caregivers to define the disease burden and unmet needs.

  • Boehringer Ingelheim Implements One Medicine Technology Platform

    For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

  • AstraZeneca Hopes To Advance Oncology RWE

    AstraZeneca is an emerging leader in the chronic lymphocytic leukemia space. It now hopes to develop treatments so patients can avoid chemotherapy, with the hope those therapies will prolong survival in patients while also producing a better quality of life.

  • How CVS, Walgreens, And Walmart Will Improve Clinical Trial Recruitment

    A new development could potentially change the patient recruitment challenge. In 2022, CVS, Walgreens, and Walmart officially entered the clinical trials space. The patient access capabilities of all three organizations may change the way drug developers access patients while also solving the patient diversity problem.